VCTC, a Derby, UK-based company which specializes in clinical trial site, received an equity investment from Sprim Global Investments.
The amount of the deal was not disclosed.
The company intends to use the funds to accelerate growth through expansion of services and access to wider cross-portfolio opportunities.
VCTC is a provider of a virtual and decentralized clinical trial site that eliminates the burden of clinical participation and facilitates the rapid recruitment of patients. Its novel virtual process expedites the generation of rich and diverse clinical data sets by bringing clinical trials to participants and providing compassionate in-home support.
The company will continue to operate as a separate business under the existing leadership of co-founders Helen Shaw and Daniel Henley, with Thomas Fratacci and Susan Dallabrida, PhD, joining the VCTC board.
Source : Finsmes
